AngioDynamics (ANGO) Tops Q3 Earnings and Revenue Estimates

Core Viewpoint - AngioDynamics reported quarterly earnings of $0.03 per share, significantly beating the Zacks Consensus Estimate of a loss of$0.13 per share, marking an earnings surprise of 123.08% [1] Financial Performance - The company posted revenues of $72 million for the quarter ended February 2025, surpassing the Zacks Consensus Estimate by 2$75.18 million [2] - Over the last four quarters, AngioDynamics has exceeded consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Performance - AngioDynamics shares have increased approximately 5.5% since the beginning of the year, contrasting with the S&P 500's decline of 4.2% [3] Future Outlook - The company's earnings outlook will be crucial for determining the sustainability of its stock price movement, with current consensus EPS estimates at -$0.09 for the coming quarter and -$0.37 for the current fiscal year [4][7] - The estimate revisions trend for AngioDynamics is currently mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Medical - Instruments industry, to which AngioDynamics belongs, is currently in the top 30% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]